Inspire Medical Systems, Inc. (INSP)
NYSE: INSP · Real-Time Price · USD
55.11
+0.04 (0.07%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Company Description
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally.
The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA.
It also develops a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway.
The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Inspire Medical Systems, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | May 3, 2018 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 1,333 |
| CEO | Timothy Herbert |
Contact Details
Address: 5500 Wayzata Blvd., Suite 1600 Golden Valley, Minnesota 55416 United States | |
| Phone | 844 672 4357 |
| Website | inspiresleep.com |
Stock Details
| Ticker Symbol | INSP |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001609550 |
| CUSIP Number | 457730109 |
| ISIN Number | US4577301090 |
| Employer ID | 26-1377674 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Timothy P. Herbert | Founder, Chairman, Chief Executive Officer and President |
| Bryan K. Phillips J.D. | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
| Carlton W. Weatherby | Chief Strategy and Growth Officer |
| Matthew J. Osberg | Executive Vice President and Chief Financial Officer |
| Jason P. Kelly | Chief Operations and Quality Officer |
| Ezgi Yagci | Vice President of Investor Relations |
| Melissa J. Mann | Chief People Officer |
| John C. Rondoni | Chief Product and Innovation Officer |
| Ivan Lubogo | SVice President of Strategic Sales |
| Andreas Henke | Executive Vice President International and MD |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 20, 2026 | ARS | Filing |
| Mar 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 20, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 9, 2026 | PRE 14A | Other preliminary proxy statements |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | 10-K | Annual Report |
| Feb 11, 2026 | 8-K | Current Report |
| Feb 10, 2026 | SCHEDULE 13G | Filing |
| Jan 12, 2026 | 8-K | Current Report |